In vivo evaluation of [123I]MNI-420: A novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain

Nuclear Medicine and Biology

Volumn 40, Issue 3, 2013, Pages 403-409

  Tavares, Adriana Alexandre dos Santos ^a   Batis, Jeffery ^a   Barret, Olivier ^b   Alagille, David ^a   Vala, Christine ^a   Kudej, Greg ^a   Koren, Andrei ^a   Cosgrove, Kelly P ^c   Nice, Katie ^d   Kordower, Jeffrey H ^d   Seibyl, John ^a,b   Tamagnan, Gilles D ^a,b  

^a Molecular NeuroImaging LLC   (United States)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

123I MNI 420; A2A receptors; Brain imaging; Caffeine; Preladenant; SPECT

Indexed keywords

7 [2 (4 (2 FLUORO 4 IODOPHENYL)PIPERAZIN 1 YL)ETHYL] 2 (FURAN 2 YL) 7H PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDIN 5 AMINE I 123; ADENOSINE A2 RECEPTOR; CAFFEINE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOACCUMULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; GAMMA CAMERA; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; PAPIO ANUBIS; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOLOGICAL PARAMETERS; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATUM TO CEREBELLUM RATIO;

ANIMALS; BRAIN; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; MACACA FASCICULARIS; MALE; PAPIO; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; RADIOACTIVE TRACERS; RECEPTOR, ADENOSINE A2A;

EID: 84875261443     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.12.005     Document Type: Article

References (32)

1. 11C]SCH442416. Eur J Nucl Med Mol Imaging 2005, 32:405-413.
2. 11C]TMSX PET. Synapse 2007, 61:778-784.
3. 2A receptors in rats. Synapse 2001, 42:164-176.
4. Müller C.E., Jacobson K.A. Recent developments in adenosine receptor ligands and theis potential as novel drugs. Biochim Biophys Acta 2011, 1808:1290-1308.
5. Svenningsson P., Hall H., Sedvall G., Fredholm B.B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997, 27:322-335.
6. 2A adenosine receptor antagonists for positron emission tomography (PET). Eur J Med Chem 2006, 41:7-15.
7. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002, 80:262-270.
8. 2a receptor. Nature 1997, 338:674-678.
9. 2A receptor knockout mice. Br J Pharmacol 2001, 134:68-77.
10. 2A receptors. Nucl Med Biol 1997, 24:187-191.
11. 2a receptor ligand. J Nucl Med 1998, 39:498-503.
12. Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76:1811-1816.
13. 11C]TMSX PET in the striata of Parkinson's disease patients. PLoS One 2011, 6:e17338.
14. Neustadt B.R., Hao J., Lindo N., Greenlee W.J., Stamford A.W., Tulshian D., et al. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett 2007, 17:1376-1380.
15. Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., Monopoli A., Ongini E., et al. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J Med Chem 2002, 45:115-126.
16. Seibyl J.P., Stobbart H.A., Martin D., Smith E., Wisniewsk G., Stoddart H.F. Evaluation of high resolution NeuroFocus SPECT device for small animal imaging. J Nucl Med 2002, 43.
17. Stoddart H.A.S., Stoddart H.F. New multidimensional reconstructions for the 12-detector, scanned focal point, single photon tomograph. Phys Med Biol 1992, 37:579-586.
18. Chang L.-T. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Med 1978, 25:638-643.
19. Innis R., Cunningham V., Delforge J., Fujita M., Gjedde A., Gunn R., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007, 27:1533-1539.
20. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000, 27:661-670.
21. Logan J., Fowler J.S., Volkow N.D., Wang G.-J., Ding Y.-S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996, 16:834-840.
22. 11C]TMSX and positron emission tomography. Eur J Nucl Med Mol Imaging 2006, 2007:5.
23. 2A receptor ligands in rat, mouse and pig brain and first ex vivo results. Eur J Pharmacol 2009, 616:107-114.
24. 2a receptor ligand. J Nucl Med 2000, 41:345-350.
25. 2A receptor antagonist treatment of Parkinson's disease. Neurology 2003, 61:293-296.
26. 2A receptor in basal ganglia. Biosci Biotechnol Biochem 2001, 65:1447-1457.
27. 2A antagonists in PD. Neurology 2002, 58:1154-1160.
28. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience 1992, 51:501-512.
29. Ascherio A., Zhang S.M., Hernán M.A., Kawachi I., Colditz G.A., Speizer F.E., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001, 50:56-63.
30. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.-H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. J Am Med Assoc 2000, 283:2674-2679.
31. 2A receptors: a new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov 2007, 2:1-21.
32. 2A receptors with positron emission tomography. Nucl Med Biol 2000, 27:541-546.